FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of Apitope

FDA Grants Orphan Status for ATX-F8-117 for the treatment of Haemophilia A patients in the US

11-Jun-2015 - Apitope announced that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration (FDA) for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors. Commenting on the ...

hemophilia A Orphan Drug Designation

Apitope Receives Orphan Designation in the European Union for ATX-F8-117 for the treatment of Haemophilia A

27-Nov-2014 - Apitope announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A.Haemophilia A is a rare chronic bleeding disorder which leads to inadequate clotting of the ...

antibodies hemophilia A Orphan Drug Designation

Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

06-Sep-2013 - Apitope announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467. Examination of the MRI results (new Gd and total Gd enhancing lesions) demonstrated a significant decrease in the number of contrast-enhancing brain lesions (CEL) in patients with relapsing ...

magnetic resonance imaging phase I studies relapsing multiple sclerosis

Apitope appoints Hayley French as Commercial Director

02-Nov-2010 - Apitope International N.V. announced that Hayley French will join its management team as Commercial Director with immediate effect. Hayley will be responsible for maximising the potential of Apitope’s technology platform. Hayley brings with her over fifteen years’ experience of negotiating ...

cooperations education Ireland +3

Apitope starts new clinical trial of its investigational multiple sclerosis treatment

19-May-2010 - Apitope announced the start of its second Phase I clinical trial of ATX-MS-1467, in patients with Multiple Sclerosis (MS). ATX-MS-1467, an investigational peptide-based therapeutic derived from Apitope’s proprietary technology platform, has already completed successfully a Phase I clinical trial ...

clinical trials Merck Serono multiple sclerosis

Apitope hires Dr. Graham Roberts as Development Director for Therapeutics

17-Jul-2009 - Apitope International N.V. announced the appointment of Dr. Graham Roberts as Development Director for Therapeutics. Among his responsibilities at Apitope, Dr Roberts will have overall responsibility for Apitope's R&D activities with an initial focus on the ATX-MS-1467 project. In January, ...

autoimmune diseases biochemistry biologics +3